Veteran Affairs Greater Los Angeles Healthcare System, 11310 Wilshire Blvd., Building 115, Los Angeles, CA 90073, USA; Vatche and Tamar Manoukian Division of Digestive Diseases, 900 Veterans Ave., Warren Hall Building, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA 90095, USA.
Vatche and Tamar Manoukian Division of Digestive Diseases, 900 Veterans Ave., Warren Hall Building, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, CA 90095, USA.
Neuropharmacology. 2018 Jan;128:255-268. doi: 10.1016/j.neuropharm.2017.10.014. Epub 2017 Oct 16.
The interaction between NMDA receptors and μ-opioid receptors in primary afferent terminals was studied by using NMDA to induce substance P release, measured as neurokinin 1 receptor internalization. In rat spinal cord slices, the μ-opioid receptor agonists morphine, DAMGO and endomorphin-2 inhibited NMDA-induced substance P release, whereas the antagonist CTAP right-shifted the concentration response of DAMGO. In vivo, substance P release induced by intrathecal NMDA after priming with BDNF was inhibited by DAMGO. ω-Conotoxins MVIIC and GVIA inhibited about half of the NMDA-induced substance P release, showing that it was partially mediated by the opening of voltage-gated calcium (Cav) channels. In contrast, DAMGO or ω-conotoxins did not inhibit capsaicin-induced substance P release. In cultured DRG neurons, DAMGO but not ω-conotoxin inhibited NMDA-induced increases in intracellular calcium, indicating that μ-opioid receptors can inhibit NMDA receptor function by mechanisms other than inactivation of Cav channels. Moreover, DAMGO decreased the ω-conotoxin-insensitive component of the substance P release. Potent inhibition by ifenprodil showed that these NMDA receptors have the NR2B subunit. Activators of adenylyl cyclase and protein kinase A (PKA) induced substance P release and this was decreased by the NMDA receptor blocker MK-801 and by DAMGO. Conversely, inhibitors of adenylyl cyclase and PKA, but not of protein kinase C, decreased NMDA-induced substance P release. Hence, these NMDA receptors are positively modulated by the adenylyl cyclase-PKA pathway, which is inhibited by μ-opioid receptors. In conclusion, μ-opioid receptors inhibit NMDA receptor-induced substance P release through Cav channel inactivation and adenylyl cyclase inhibition.
在初级传入末梢中,通过使用 NMDA 诱导 P 物质释放来研究 NMDA 受体和 μ 阿片受体之间的相互作用,其测量方法为神经激肽 1 受体内化。在大鼠脊髓切片中,μ 阿片受体激动剂吗啡、DAMGO 和内吗啡肽-2 抑制 NMDA 诱导的 P 物质释放,而拮抗剂 CTAP 使 DAMGO 的浓度反应右移。在体内,BDNF 引发的鞘内 NMDA 诱导的 P 物质释放被 DAMGO 抑制。ω-Conotoxin MVIIC 和 GVIA 抑制了约一半的 NMDA 诱导的 P 物质释放,表明它部分由电压门控钙(Cav)通道的开放介导。相比之下,DAMGO 或 ω-Conotoxin 不会抑制辣椒素诱导的 P 物质释放。在培养的 DRG 神经元中,DAMGO 而不是 ω-Conotoxin 抑制 NMDA 诱导的细胞内钙增加,表明 μ 阿片受体可以通过 Cav 通道失活以外的机制抑制 NMDA 受体功能。此外,DAMGO 减少了 P 物质释放的 ω-Conotoxin 不敏感成分。ifenprodil 的强效抑制表明这些 NMDA 受体具有 NR2B 亚基。腺苷酸环化酶和蛋白激酶 A(PKA)的激活剂诱导 P 物质释放,该释放被 NMDA 受体阻滞剂 MK-801 和 DAMGO 减少。相反,腺苷酸环化酶和 PKA 的抑制剂,但不是蛋白激酶 C 的抑制剂,减少了 NMDA 诱导的 P 物质释放。因此,这些 NMDA 受体通过腺苷酸环化酶-PKA 途径被正向调节,而该途径被 μ 阿片受体抑制。总之,μ 阿片受体通过 Cav 通道失活和腺苷酸环化酶抑制抑制 NMDA 受体诱导的 P 物质释放。